文献速递胸部肿瘤放疗放疗物理与技术

Ⅲ期非小细胞肺癌自适应调强放疗联合同步推量是否常规获益

Adaptive intensity-modulated radiotherapy with simultaneous integrated boost for stage III non-small cell lung cancer: Is a routine adaptation beneficial?
PubMed 文献 · Radiother Oncol · 2021-02-23

自适应计划使危及器官剂量显著下降,可能降低急性放射性肺炎和食管炎风险,且未增加肿瘤复发。

要点

  • 前20次放疗后肿瘤GTV中位缩小38.2%,自适应计划显著降低危及器官剂量。
  • 自适应使平均肺剂量降低74.8 cGy,平均食管剂量降低183.1 cGy。
  • 自适应可能降低RP2概率3%、RE2风险5%,未增加肿瘤复发。

核心结论

  • 常规自适应同步推量调强放疗可显著降低周围正常组织剂量,可能降低急性放射性肺炎和食管炎风险,且不增加肿瘤复发风险。

主要发现

  • 前20次放疗(42至44 Gy)后GTV中位缩小38.2%。
  • 自适应计划使平均肺剂量平均降低74.8 cGy,平均食管剂量降低183.1 cGy。
  • 自适应可能使RP2概率降低3%,RE2风险降低5%。
  • 自放疗开始估算的中位无进展生存期为12.5个月。

关键数值与推荐

  • 危及器官按RTOG 1106图谱勾画。
  • 常用肺和食管剂量指标与RP2和RE2显著相关。
  • 危及器官剂量较高或肿瘤缩小较大的亚组可能获得更多剂量和毒性获益。

临床怎么用

  • 对Ⅲ期非小细胞肺癌行同步推量调强放疗时,可考虑在前20次后常规重新CT模拟并制定自适应计划以降低危及器官剂量。
  • 危及器官剂量较高或肿瘤缩小较大的患者可能从自适应计划中获益更多。

局限性

  • 本研究为回顾性研究,样本量有限。
  • 自适应对RP2和RE2风险的降低为模型估算值,需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Tumor and anatomical changes during radiotherapy have been observed in stage III non-small cell lung cancer (NSCLC) from many previous studies. We hypothesized that a routinely scheduled adaptive radiotherapy would have clinical important dose benefits to lower the risk of toxicities, without increasing the tumor recurrences. METHODS: We retrospectively reviewed 92 consecutive patients with inoperable stage III NSCLC between November 2017 and March 2019. All eligible patients should received simultaneously integrated boost (SIB) using intensity-modulated radiation therapy (IMRT). A mid-treatment CT simulation and a new adapted plan were routinely given after the first 20 fractions. The organs at risk (OARs) were delineated per RTOG 1106 atlas. Dose-volume histograms were quantitatively compared between the initial and composite adaptive plans. Logistic regression was applied to analyze the dose-response relationship. Clinical endpoints included acute symptomatic radiation pneumonitis (RP2) and esophagitis (RE2), local and regional tumor control, and progression-free survival (PFS). RESULTS: Sixty-four eligible patients received adaptive SIB-IMRT were consecutively included. The GTVs reduced by a median of -38.2% after 42 to 44 Gy in 20 fractions of radiotherapy. By adapting to tumor and anatomical changes, dosimetric parameters of OARs decreased significantly. The mean lung dose decreased by an average of -74.8 cGy, and mean esophagus dose was lower by 183.1 cGy. We found grade 2 or higher acute RP in 11 patients (17.2%), and RE2 in 28 patients (43.8%). Commonly used lung and esophagus dose metrics were significantly associated with RP2 and RE2. The adaptation could reduce RP2 probability by 3%, and RE2 risk by 5%. Subgroups with higher OARs dose or larger tumor shrinkage may get more dose and toxicities benefits. The estimated median PFS was 12.5 months from the start of radiotherapy. CONCLUSIONS: We demonstrated that the routinely adaptive SIB-IMRT strategy could significantly reduce the dose to surrounding normal tissues, potentially lower the associated acute RP and RE, without increasing the risk of tumor recurrences.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Meng Y, Luo W, Xu H, et al. Adaptive intensity-modulated radiotherapy with simultaneous integrated boost for stage III non-small cell lung cancer: Is a routine adaptation beneficial? Radiother Oncol. 2021. PMID: 33636232. doi:10.1016/j.radonc.2021.02.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。